...
首页> 外文期刊>Integrative cancer therapies >The National cancer institute best case series program: A summary of cases of cancer patients treated with unconventional therapies in India
【24h】

The National cancer institute best case series program: A summary of cases of cancer patients treated with unconventional therapies in India

机译:美国国家癌症研究所最佳病例系列计划:印度非常规疗法治疗的癌症患者病例摘要

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives. The National Cancer Institute (NCI) Best Case Series (BCS) Program provides an independent review of medical records, imaging, and pathology of cancer patients treated with unconventional therapies. The goal of the NCI BCS Program is to identify preliminary evidence of tumor regression and assess whether there is sufficient evidence to move forward with NCI-initiated research. The objective was to review case reports submitted by 4 practitioners from India who used ayurvedic and homeopathic therapies to treat cancer. Design. Retrospective review of case reports of 4 practitioners from India who used ayurvedic and homeopathic therapies to treat cancer. Results. A total of 68 cases were submitted to the NCI BCS Program. Fifty-one percent of the cases represented homeopathy and 49% ayurveda. Of the 68 cases, 32 (47%) of the cases were collectively designated as "persuasive" (P) or "supportive"(S), and 36 (53%) as "not evaluable." Forty-one (60%) patients did not have any prior conventional treatment. Conclusion. The challenge for submitters rests in their ability to supply sufficient documentation for the NCI BCS Program. The NCI BCS Program represents a unique avenue for the rigorous evaluation of "best cases" to identify complementary and alternative medicine modalities that are promising for prospective preclinical evaluation or prospective research.
机译:目标。美国国家癌症研究所(NCI)最佳病例系列(BCS)计划对使用非常规疗法治疗的癌症患者的病历,影像学和病理学进行独立审查。 NCI BCS计划的目标是确定肿瘤消退的初步证据,并评估是否有足够的证据来推动NCI开展的研究。目的是审查印度的4位使用印度草药疗法和顺势疗法治疗癌症的从业者提交的病例报告。设计。回顾性回顾了印度的4位使用印度草药疗法和顺势疗法治疗癌症的从业者的病例报告。结果。总共有68个案例已提交给NCI BCS计划。 51%的病例代表顺势疗法,49%的阿育吠陀。在这68个案例中,有32个(47%)被共同指定为“有说服力”(P)或“支持”(S),而36个(53%)被定为“不可评估”。四十一(60%)例患者未曾接受过任何常规治疗。结论。提交者面临的挑战在于他们能否为NCI BCS计划提供足够的文档。 NCI BCS计划代表了对“最佳病例”进行严格评估的独特途径,可以识别出有希望用于前期临床前评估或前瞻性研究的补充和替代医学方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号